These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 10217310

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
    Hoyes KP, Porter JB.
    Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site.
    Porter JB, Abeysinghe RD, Hoyes KP, Barra C, Huehns ER, Brooks PN, Blackwell MP, Araneta M, Brittenham G, Singh S.
    Br J Haematol; 1993 Sep; 85(1):159-68. PubMed ID: 8251385
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds.
    Porter JB, Singh S, Hoyes KP, Epemolu O, Abeysinghe RD, Hider RC.
    Adv Exp Med Biol; 1994 Sep; 356():361-70. PubMed ID: 7887242
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The pharmacokinetics of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rats.
    Epemolu OR, Singh S, Hider RC, Damani LA.
    Drug Metab Dispos; 1992 Sep; 20(5):736-41. PubMed ID: 1358580
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evidence that desferrioxamine cannot enter cells by passive diffusion.
    Lloyd JB, Cable H, Rice-Evans C.
    Biochem Pharmacol; 1991 May 01; 41(9):1361-3. PubMed ID: 2018567
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
    Bergeron RJ, Streiff RR, Wiegand J, Luchetta G, Creary EA, Peter HH.
    Blood; 1992 Apr 01; 79(7):1882-90. PubMed ID: 1558978
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of iron chelation on the in-vitro growth of Leishmania promastigotes.
    Soteriadou K, Papavassiliou P, Voyiatzaki C, Boelaert J.
    J Antimicrob Chemother; 1995 Jan 01; 35(1):23-9. PubMed ID: 7768775
    [Abstract] [Full Text] [Related]

  • 17. Uptake of microparticles by rat visceral yolk sac.
    Pratten MK, Lloyd JB.
    Placenta; 1997 Sep 01; 18(7):547-52. PubMed ID: 9290150
    [Abstract] [Full Text] [Related]

  • 18. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones.
    Singh S, Epemolu RO, Dobbin PS, Tilbrook GS, Ellis BL, Damani LA, Hider RC.
    Drug Metab Dispos; 1992 Sep 01; 20(2):256-61. PubMed ID: 1352218
    [Abstract] [Full Text] [Related]

  • 19. Desferrithiocin and desferrioxamine B. Cellular pharmacology and storage iron mobilization.
    Jin Y, Baquet A, Florence A, Crichton RR, Schneider YJ.
    Biochem Pharmacol; 1989 Oct 01; 38(19):3233-40. PubMed ID: 2818622
    [Abstract] [Full Text] [Related]

  • 20. Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.
    Huang XP, Thiessen JJ, Spino M, Templeton DM.
    Int J Hematol; 2010 Apr 01; 91(3):401-12. PubMed ID: 20213118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.